Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2 2Phase 1/2 2Phase NA 1Phase 3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2Neuroblastoma 2

Interventions

gallium Ga 68 dotatate 690Y-octreotide, DOTA-Tyr(3)- 3Magnetic Resonance Spectroscopy 23-Iodobenzylguanidine 2lutetium Lu 177 dotatate 1lanreotide 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Single Photon Emission Computed Tomography Computed Tomography 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Metformin 1Iodine-123 1Ga(III)-DOTATOC 168Ga-pentixafor 168Ga-FAPI 164Cu-SARTATE 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neuroendocrine Tumors × 3-Iodobenzylguanidine × Clear all
NCT04510311 2025-01-10

Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Completed
32 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03044977 2023-08-16

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

University of Iowa

Phase EARLY_PHASE1 Active not recruiting
20 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡